This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pivonello, R. Articles by Lombardi, G. Search for Related Content PubMed PubMed Citation Articles by Pivonello, R. Articles by Lombardi, G.

Impairment of Bone Status in Patients with Central Diabetes Insipidus*

Department of Molecular and Clinical Endocrinology and Oncology, "Federico II" University (R.P., A.C., C.D.S., G.F., A.F., G.L.); and CNR, Biomorphological and Functional Sciences (M.K., M.S.), Naples, Italy

Address all correspondence and requests for reprints to: Annamaria Colao, M.D., Ph.D., Department of Molecular and Clinical Endocrinology and Oncology, "Federico II" University, via Sergio Pansini, 5, 80131, Naples, Italy. E-mail: rpivone{at}tin.it

The aim of the current study was to evaluate the biochemical parameters of bone metabolism and the bone mineral density (BMD) in patients with central diabetes insipidus, either treated or not treated with endonasal desmopressin.

Eighteen patients with central diabetes insipidus and 18 sex- and age-matched healthy subjects entered the study. The patients were divided into 2 groups: patients who did not receive treatment with desmopressin for at least 1 yr (group 1), and patients chronically treated with desmopressin since the diagnosis of diabetes insipidus (group 2). Serum osteocalcin and urinary cross-linked N-telopeptide of type I collagen levels were measured in all patients and controls using RIA and enzyme-linked immunosorbent assay kits, respectively. BMD was measured at the lumbar spine (L1-L4) and at the femoral neck in all subjects, using a Hologic QDR 1000 analyzer (Hologic Inc., Waltham, MA).

Serum osteocalcin concentrations were significantly lower, both in patients of group 1 and group 2, compared with healthy subjects (5.1 ± 0.6 and 4.5 ± 0.3 vs. 7.9 ± 0.2 µg/L, P < 0.05), whereas urinary cross-linked N-telopeptide of type I collagen concentrations were similar in the three groups of subjects (72.8 ± 2.2, 71.6 ± 2.7, and 64.6 ± 1.7 nmol bone collagen equivalent/mmol creatinine). BMD was significantly decreased in patients of groups 1 and 2, compared with controls, both at lumbar spine (0.84 ± 0.06 and 0.87 ± 0.04 vs. 1.01 ± 0.02 g/cm², P < 0.05) and femoral neck (0.78 ± 0.06 and 0.80 ± 0.04 vs. 0.93 ± 0.02 g/cm², P < 0.05). A significant inverse correlation was found between disease duration and BMD values, evaluated as T scores, both at lumbar spine (group 1: r = -0.952, P < 0.005; group 2: r = -0.921, P < 0.001) and at femoral neck (group 1: r = -0.914, P < 0.05; group 2: r = -0.683, P < 0.05).

In conclusion, patients with central diabetes insipidus had a significant bone impairment, compared with healthy subjects. Replacement with endonasal desmopressin at standard doses was not able to prevent or reverse the bone impairment. These findings suggest that, in patients with central diabetes insipidus, bone status analysis is mandatory; and a bone-loss preventing treatment might be beneficial.

This article has been cited by other articles:

				R. Pivonello, A. De Bellis, A. Faggiano, F. Di Salle, M. Petretta, C. Di Somma, S. Perrino, P. Altucci, A. Bizzarro, A. Bellastella, et al. Central Diabetes Insipidus and Autoimmunity: Relationship between the Occurrence of Antibodies to Arginine Vasopressin-Secreting Cells and Clinical, Immunological, and Radiological Features in a Large Cohort of Patients with Central Diabetes Insipidus of Known and Unknown Etiology J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1629 - 1636. [Abstract] [Full Text] [PDF]

				R. Pivonello, A. Faggiano, C. Di Somma, M. Klain, M. Filippella, M. Salvatore, G. Lombardi, and A. Colao Effect of a Short-Term Treatment with Alendronate on Bone Density and Bone Markers in Patients with Central Diabetes Insipidus J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2349 - 2352. [Abstract] [Full Text]

				A. Colao, C. Di Somma, R. Pivonello, S. Loche, G. Aimaretti, G. Cerbone, A. Faggiano, G. Corneli, E. Ghigo, and G. Lombardi Bone Loss Is Correlated to the Severity of Growth Hormone Deficiency in Adult Patients with Hypopituitarism J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1919 - 1924. [Abstract] [Full Text]